🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Longitudinal CRP kinetics (CRP Flare 🔥) predicts immunotherapy response within the first month in NSCLC! Great tool for therapy monitoring and as an integral biomarker for biomarker-directed study design Niklas Klümper Tobias Bald @IEO_BaldLab IEO_Bonn ImmunoSensation Rheinische Friedrich-Wilhelms-Universität Bonn

🔬🦠🧪 Wir kommen zu Euch! 🫁🧬🧫🫀 #Wissenschaft zum Anfassen auf dem Marktplatz #Bonn und in der #Stadtbibliothek Bonn 🗓️ Samstag, 30.04.2022, 10:00 - 18:00 #TagDerImmunologie Programm: immunosensation.de/news/talks_eve… Rheinische Friedrich-Wilhelms-Universität Bonn Uniklinik Bonn #dayofimmunology #science #immunology

Interested in learning about science, while have a cool drink? Talented scientists are sharing their latest research today #PintOfScience2022 , including Fenna Feenstra from the IEO_BaldLab Rheinische Friedrich-Wilhelms-Universität Bonn

Well done Fenna 👏🥳

The easy-to-implement mGPS performed significantly better than the therapeutically relevant IMDC score Annals of Oncology. Future trials on mRCC should incorporate the mGPS! Congrats to the leading authors Jonas and Niklas Niklas Klümper from IEO. Uniklinik Bonn ImmunoSensation

In the phase III #IMmotion151 trial of metastatic #RenalCellCarcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. #ReadNow on UroToday > bit.ly/3B5idWb Annals of Oncology Uniklinik Bonn IEO_HölzelLab

Happy to share our work: Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance Clinical Cancer Research aacrjournals.org/clincancerres/… Follow our tweetorial about this clinically important data 1/12

Congratulations🎉Niklas Klümper

Herzlichen Glückwunsch 🎉🎊

Great news in #Tumor #Immunology #research: immunosensation.de/news/artificia… "InterpreTME" recieves funding by Bildungsmisererepublik Deutschland - BRDigung to develop new AI tools to analyse the tumor microinvironment. Congratulations to our members Kevin Thurley IEO_HölzelLab Jan Hasenauer and Alexander Effland!

Happy to share our work: Early CRP kinetics predicts immunotherapy response in NSCLC in the phase III OAK trial Jonas Saal JNCI academic.oup.com/jncics/advance…. Follow our tweetorial about this simple and easy-to-implement immunotherapy biomarker 1/7

Congratulations 🥳🎊

We're grateful to European Urology for featuring our insights on the power of integrating Nectin-4 PET/CT in guiding Nectin-4 targeting therapies like Enfortumab vedotin for patients with met UC. #PrecisionMedicine authors.elsevier.com/a/1hCKa14kplv9… Follow our tweetorial 1/6

Important work led by Jonas Saal and Niklas Klümper from IEO_Bonn just published in JAMA Oncology Developing an Ideal Risk Stratification Model for mRCC 📷Fabulous Editorial from Neeraj Agarwal, MD, FASCO Georges Gebrael Gliceida Galarza, MD tinyurl.com/3dhkjt9d Kidney Cancer UroToday.com OncoAlert

A new research in JAMA Network shows that longitudinal measurement of systemic inflammatory response (through mGPS) in patients with mRCC provides valuable prognostic information and could integrate radiological staging in therapy monitoring jamanetwork.com/journals/jamao…

Exciting Update from EV301 trial! 🚀EV maintains survival benefit after ~2 years of follow-up. BUT: Who benefits most from EV?🎯 Our data suggest NECTIN4 as a promising predictive biomarker! OncoAlert UroToday.com Markus Eckstein Viktor Grünwald aacrjournals.org/clincancerres/… #oncology

We are happy to share our new study published today Journal of Clinical Oncology (👉 ascopubs.org/doi/10.1200/JC…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer. With a huge contribution of our multinational team we uncovered

Very happy to share our study published Journal of Clinical Oncology ! ascopubs.org/doi/full/10.12… ➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4

We are happy to share our current manuscript: In an exploratory post-hoc analysis of IMmotion151 (mRCC, atezo + beva) and IMvigor211 (mUC, atezo), in which we correlated baseline electrolyte concentration with ICB response and outcome in an unbiased manner, we made an interesting

Interesting work from Niklas Klümper et al —Na levels may module ICB response. Still so much unknown in this area. Congrats for the elegant work Niklas!